NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cellis

Cellis

Private
WarsawHealthcare & Life Scienceshttps://cellis.eu/

Last Round

Grant

May 5, 2026

Total Funding Raised

$31.53M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cellis is a biotechnology company that develops cell-based oncology therapies using a proprietary Macrophage Drug Conjugate (MDC) platform to target tumor microenvironments.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyMDCmacrophage drug conjugateoncology therapycell therapycellular therapydiagnostic solutionsmedical devicesbiotech equipmentlaboratory diagnosticsclinical diagnosticsclinical trialsdrug developmentbiotech startuplife sciences

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cellis Comps

Public and private peers based on sector, stage, and business model.

Cellis comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cellis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 5, 2026
Series BFeb 1, 2026
GrantDec 17, 2024
GrantNov 28, 2024
GrantNov 1, 2022

Key People

Founding team and executive leadership

Robert Aleksandrowicz

Chief Executive Officer

Executive Team

Tomasz Rygiel

Chief Technology Officer

Executive Team

Przemysław Mencel FCMA

Chief Financial Officer

Executive Team

Cellis Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 5, 2026

    Received grant funding from the Ministry of Funds and Regional Policy.

  • Nov 1, 2022

    Secured $2.47M from the European Innovation Council.

Cellis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cellis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cellis's valuation, stock price, and market status.

Firmographic Details

HeadquartersWarsaw
Employee Range12
Year Founded2015
Last FundingMay 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.